Management of patients with locally advanced breast cancer

Current Oncology Reports

Volumn 6, Issue 1, 2004, Pages 53-61

  Newman, Lisa A ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; TAMOXIFEN; THIOTEPA; TUMOR MARKER; VINCRISTINE; VINDESINE;

ADVANCED CANCER; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; MEDICAL DECISION MAKING; METASTASIS; MORBIDITY; MORTALITY; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PATIENT SELECTION; REVIEW; SENTINEL LYMPH NODE BIOPSY; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

EID: 3142550875     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-996-0010-z     Document Type: Review

References (73)

1. Weir HK, Thun MJ, Hankey BF, et al.: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003, 95:1276-1299.
2. Singletary SE, Allred C, Ashley P, et al.: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20:3628-3636.
3. Olivotto IA, Chua B, Allan SJ, et al.: Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. J Clin Oncol 2003, 21:851-854.
4. Brito RA, Valero V, Buzdar AU, et al.: Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 2001, 19:628-633.
5. American College of Surgeons National Cancer Data Base; 2000. http://www.facs.org/cancer/ncdb/index.html
6. Haagensen C, Stout A: Carcinoma of the breast II. Criteria of operability. Ann Surg 1943, 118:859.
7. Arnold DJ, Lesnick GJ: Survival following mastectomy for stage III breast cancer. Am J Surg 1979, 137:362-366.
8. Fracchia AA, Evans JF, Eisenberg BL: Stage III carcinoma of the breast: a detailed analysis. Ann Surg 1980, 192:705-710.
9. Harris JR, Sawicka J, Gelman R, Hellman S: Management of locally advanced carcinoma of the breast by primary radiation therapy. Int J Radiat Oncol Biol Phys 1983, 9:345-349.
10. Rao DV, Bedwinek J, Perez C, et al.: Prognostic indicators in stage III and localized stage IV breast cancer. Cancer 1982, 50:2037-2043.
11. Rubens RD, Armitage P, Winter PJ, et al.: Prognosis in inoperable stage III carcinoma of the breast. Eur J Cancer 1977, 13:805-811.
12. Kaufmann M, von Minckwitz G, Smith R, et al.: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003, 21:2600-2608.
13. Broadwater JR, Edwards MJ, Kuglen C, et al.: Mastectomy following preoperative chemotherapy: strict operative criteria control operative morbidity. Ann Surg 1991, 213:126-129.
14. McCready DR, Hortobagyi GN, Kau SW, et al.: The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989, 124:21-25.
15. De Lena M, Varini M, Zucali R, et al.: Multimodal treatment for locally advanced breast cancer: results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 1981, 4:229-236.
16. Perloff M, Lesnick GJ, Korzun A, et al.: Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 1988, 6:261-269.
17. Papaioannou A, Lissaios B, Vasilaros S, et al.: Pre- and postoperative chemoendocrine treatment with or without postoperative radiotherapy for locally advanced breast cancer. Cancer 1983, 51:1284-1290.
18. Hortobagyi GN, Ames FC, Buzdar AU, et al.: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988, 62:2507-2516.
19. Lippman ME, Sorace RA, Bagley CS, et al.: Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. NCI Monogr 1986, 1:153-159.
20. Mauriac L, Durand M, Avril A, Dilhuydy JM: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm: results of a randomized trial in a single centre. Ann Oncol 1991, 2:347-354.
21. Mauriac L, MacGrogan G, Avril A, et al.: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999, 10:47-52.
22. Schwartz GF, Birchansky CA, Komarnicky LT, et al.: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994, 73:362-369.
23. Schwartz GF, Lange AK, Topham AK: Breast conservation following induction chemotherapy for locally advanced carcinoma of the breast (stages IIB and III): a surgical perspective. Surg Oncol Clin N Am 1995, 4:657-669.
24. Powles TJ, Hickish TF, Makris A, et al.: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995, 13:547-552.
25. Makris A, Powles TJ, Ashley SE, et al.: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998, 9:1179-1184.
26. Fisher B, Brown A, Mamounas E, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-2493.
27. Fisher B, Bryant J, Wolmark N, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
28. Kuerer HM, Newman LA, Smith TL, et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
29. Newman LA, Buzdar AU, Singletary SE, et al.: A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol 2002, 9:228-234.
30. Newman LA, Kuerer HM, Fornage B, et al.: Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 2001, 181:313-318.
31. Samant R, Ganguly P: Staging investigations in patients with breast cancer: the role of bone scans and liver imaging. Arch Surg 1999, 134:551-554.
32. Biffi R, De Braud F, Orsi F, et al.: A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 2001, 92:1204-1212.
33. Singletary SE, McNeese MD, Hortobagyi GN: Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992, 69:2849-2852.
34. Recht A, Edge SB, Solin LJ, et al.: Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1539-1569.
35. McIntosh SA, Ogston KN, Payne S, et al.: Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg 2003, 185:525-531.
36. Mamounas E: Preliminary results of the NSABP B-27 Trial. Presented at San Antonio Breast Cancer Symposium. San Antonio, TX, December 10-13, 2001.
37. Green MC, Buzdar AU, Smith T, et al.: Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting povides improved pathologic complete remission (PCR) rates compared to standard paclitaxel followed by FAC therapy: preliminary results of an ongoing prospective randomized trial [abstract]. Proc ASCO 2001, 20:129.
38. Smith IC, Heys SD, Hutcheon AW, et al.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20:1456-1466.
39. Heys SD, Hutcheon AW, Sarkar TK, et al.: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002, 3(Suppl 2):S69-S74.
40. Dixon JM, Anderson TJ, Miller WR: Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 2002, 38:2214-2221.
41. Ellis M, Coop A: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19:3808-3816.
42. Helvie MA, Joynt LK, Cody RL, et al.: Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 1996, 198:327-332.
43. Delille JP, Slanetz PJ, Yeh ED, et al.: Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology 2003, 228:63-69.
44. Abraham D, Jones R, Jones S, et al.: Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996, 78:91-100.
45. Wahl R, Zasadny K, Helvie M: Metabolic monitoring of breast cancer chemohormonal therapy using positron emission tomography: Initial evaluation. J Clin Oncol 1993, 11:2101-2111.
46. Mezi S, Primi F, Capoccetti F, et al.: In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography. Int J Oncol 2003, 22:1233-1240.
47. Wilczek B, von Schoultz E, Bergh J, et al.: Early assessment of neoadjuvant chemotherapy by FEC-courses of locally advanced breast cancer using 99mTc-MIBI. Acta Radiol 2003, 44:284-287.
48. Pusztai L, Ayers M, Stec J, Hortobagyi GN: Clinical application of cDNA microarrays in oncology. Oncologist 2003, 8:252-258.
49. Newman LA, Kuerer HM, Hunt KK, et al.: Feasibility of immediate breast reconstruction for locally advanced breast cancer. Ann Surg Oncol 1999, 6:671-675.
50. Styblo T, Lewis M, Carlson G, et al.: Immediate breast reconstruction for stage III breast cancer using transverse rectus abdominis musculotaneous (TRAM) flap. Ann Surg Oncol 1996, 3:375-380.
51. Buchholz TA, Strom EA, Perkins GH, McNeese MD: Controversies regarding the use of radiation after mastectomy in breast cancer. Oncologist 2002, 7:539-546.
52. Woodward W, Strom E, Tucker S, et al.: Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 2003, 57:336-344.
53. Bedrosian I, Reynolds C, Mick R, et al.: Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000, 88:2540-2545.
54. Chung M, Ye W, Giuliano A: Role for sentinel lymph node dissection in the management of large (> or + 5 cm) invasive breast cancer. Ann Surg Oncol 2001, 8:688-692.
55. Breslin TM, Cohen L, Sahin A, et al.: Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000, 18:3480-3486.
56. Nason KS, Anderson BO, Byrd DR, et al.: Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000, 89:2187-2194.
57. Haid A, Tausch C, Lang A, et al.: Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer 2001, 92:1080-1084.
58. Fernandez A, Cortes M, Benito E, et al.: Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 2001, 22:361-366.
59. Tafra L, Verbanac K, Lannin D: Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 2001, 182:312-315.
60. Stearns V, Ewing CA, Slack R, et al.: Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002, 9:235-2342.
61. Julian TB, Dusi D, Wolmark N: Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2002, 184:315-317.
62. Miller AR, Thomason VE, Yeh IT, et al.: Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 2002, 9:243-247.
63. Brady E: Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J 2002, 8:97- 100.
64. Piato J, Barros A, Pincerato K, et al.: Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy: a pilot study. Eur J Surg Oncol 2002, 29:118-120.
65. Schwartz GF, Meltzer AJ: Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J 2003, 9:374-379.
66. Mamounas E: Accuracy of sentinal node biopsy after neoadjuvant chemotherapy in breast cancer: updated results from NSABP B-27 [abstract]. Proc ASCO 2002, 21:140.
67. Sabel MS, Schott AF, Kleer CG, et al.: Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 2003, 186:102-105.
68. Zirngbl C, Steinfeld-Birg D, Vogt H, et al.: Sentinel lymph node biopsy before neoadjuvant chemotherapy: conservation of breast and axilla [abstract]. Presented at San Antonio Breast Cancer Symposium. San Antonio, TX, December 11-14, 2002.
69. Downey R, Rusch V, Hsu F, et al.: Chest wall resection for locally recurrent breast cancer: Is it worthwhile? J Thorac Cardiovasc Surg 2000, 119:420-428.
70. Chagpar A, Meric-Bernstam F, Hunt K, et al.: Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol 2003, 10:628-634.
71. Scholl SM, Fourquet A, Asselain B, et al.: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994, 30A:645-652.
72. Scholl SM, Pierga JY, Asselain B, et al.: Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 1995, 31A:1969-1975.
73. Balch GC, Miethani SK, Richards KR, et al.: Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol 2003, 10:616-621.